Anika Therapeutics Q3 revenue rises on commercial channel growth
Overview
Osteoarthritis solutions maker's Q3 revenue rose 10% yr/yr, driven by 17% commercial channel growth
Company posted adjusted net income of $3.9 mln, reversing a loss in prior-year period
Anika secured new 10-year Hyvisc partnership and raised lower end of 2026 revenue guidance
Outlook
Anika raises lower end of 2026 revenue growth guidance to 6%-10% from 5%-10%
Company lifts 2026 adjusted EBITDA margin outlook to 15%-17% from 13%-17%
Anika expects 2027 total revenue growth to be flat to 5%
Result Drivers
COMMERCIAL CHANNEL GROWTH - Co said 17% yr/yr growth in commercial channel drove overall revenue increase, supported by international viscosupplement and Integrity adoption
INTEGRITY PRODUCT EXPANSION - Integrity revenue grew more than 30% yr/yr, aided by larger implant sizes expanding use into foot & ankle and knee applications
OEM CHANNEL EXECUTION - Co said OEM channel revenue rose 5% yr/yr, supported by Hyvisc growth and J&J DePuy Synthes sales
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $30.59 mln | $29.44 mln (2 Analysts) |
Q3 Net Loss | $311,000 | ||
Q3 Gross Profit | $18.84 mln | ||
Q3 Income from Operations | -$712,000 | ||
Q3 Pretax Loss | $322,000 |
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Anika Therapeutics Inc is $23.00, about 19% above its November 5 closing price of $19.33
The stock recently traded at 78 times the next 12-month earnings vs. a P/E of 73 three months ago
Reuters Recommended Reads
Nov 4 - Zimmer Biomet Q3 sales beat estimates, raises FY outlook
Nov 4 - Edwards Lifesciences Q3 sales beat on TMTT portfolio adoption
Nov 5 - Artivion Q3 revenue beats analyst expectations driven by On-X growth
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)